Acid Pocket: Position and Aspiration
Acid Pocket: Different Position and Chemical Content Between Healthy Volunteers and GERD Patients
1 other identifier
interventional
70
1 country
1
Brief Summary
Gastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with proton pump inhibitors (PPI). Nevertheless, only 60-70% of GERD patients report complete symptom relief with this therapy. As the mechanisms underlying symptom perception in PPI resistant patients are not fully understood, there is currently no adequate therapy available. It is becoming increasingly clear that reflux, especially in the postprandial period, occurs from a reservoir of acid floating on top of the meal: the so-called "acid pocket". In this study, we aim to investigate further the acid pocket by determining its exact position and chemical contents between healthy volunteers, GERD patient who respond well and bad to PPI therapy and GERD patients with barrett's esophagus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2014
CompletedFirst Submitted
Initial submission to the registry
July 17, 2014
CompletedFirst Posted
Study publicly available on registry
July 24, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2017
CompletedFebruary 10, 2023
February 1, 2023
3.5 years
July 17, 2014
February 7, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
acid pocket position
Acid position will be determined relatively to the lower esophageal sfincter. Differences in position between healthy volunteers, PPI responders, PPI non-responders and patients with barrett esophagus will be evaluated
participants will be followed for 24 hours
Secondary Outcomes (1)
number of reflux episodes
24 hours
Other Outcomes (1)
acid pocket contents
1 year
Study Arms (5)
healthy volunteers
OTHERhealthy volunteers (no gastric complains)
PPI responders
OTHERproven reflux, good symptom relief upon PPI therapy
PPI non-responders
OTHERproven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
Barrett - no dysplasia
OTHERproven barrett with no dysplasia on biopsies
barrett - high grade dysplasia
OTHERproven barrett with high grade dysplasia on biopsies
Interventions
a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
Eligibility Criteria
You may qualify if:
- signed informed consent
- older than 18 years
- fit to criteria of 'study population' (HV, PPI responder, PPI non-responder, Barrett)
You may not qualify if:
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- KU Leuvenlead
Study Sites (1)
Catholic University Leuven
Leuven, 3000, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Guy Boeckxstaens, MD, PhD
Catholic University Leuven
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
July 17, 2014
First Posted
July 24, 2014
Study Start
July 1, 2014
Primary Completion
December 31, 2017
Study Completion
December 31, 2017
Last Updated
February 10, 2023
Record last verified: 2023-02